Abstract 1958P
Background
ADT is an established treatment for PCa, influencing different aspects of tumor biology. The study aimed to assess expression of EMT (E- and N-cadherins (cad)) and CSC (CD44, CD133) markers as well as androgen (AR) and estrogen (ERα, ERβ) receptors and transforming growth factor beta type II receptor (TβRII) (an EMT regulator) in localized PCa samples after ADT.
Methods
56 radical prostatectomy cases were analyzed. 15 of them had 3-6 months of ADT before surgery. Double immunofluorescent staining was used. For E-cad and CD44 staining intensity was assessed, for CD133 – presence of staining, for N-cad– weighed staining index (WSI) and for AR, ERα, ERβ and TβRII – total staining scores (TSS) per case.
Results
In the studied cohort expression of EMT and CSC markers didn’t differ significantly in cases after ADT and without it (pχ2=0.71 for CD133, pMann-Whitney>0,05 for all other markers), that may assume that at least at the early stage of PCa development short-term ADT doesn’t influence these phenotypes. AR and ER expression both in stroma and epithelium didn’t differ significantly, except for ERβ in cancer cells nuclei, that appeared to be higher after ADT (TSS 6.00 vs. 3.25, pMann-Whitney=0.042). Expression of TβRII appeared to be significantly higher for nuclear and lower for membranous staining in ADT cases (Mann-Whitney test, TSS 2.33 vs. 1.20, p=0.002 and 0 vs. 0.58, p<0.001, respectively). Only in ADT cases CD44 was significantly higher in CD133+ tumors, and N-cad WSI correlated with CD44 expression, while ERα in both stroma and cancer cells correlated with epithelial AR (r=0.55 and r=0.54, pSpearman<0,05), though these associations were not seen in cases without ADT. Also moderate direct correlation was seen between nuclear TβRII and E-cad (r=0.52, pSpearman<0,05). Markers expression in pre-ADT biopsies and their dynamic changes on ADT could not be assessed.
Conclusions
ADT influences TβRII and ERβ expression in cancer cells and also modulates EMT and CSC markers and regulators correlations, that may assume that though ADT alone is not sufficient to induce EMT or CSC phenotypes, it may modulate intra-tissue interactions of signaling cascades and alter cell responses to regulating signals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Puchinskaya.
Funding
Belarusian Republican Foundation for Fundamental Research, grants No. M14M-143, M19M-123.
Disclosure
M. Puchinskaya: Financial Interests, Personal, Invited Speaker: Roche.
Resources from the same session
2008P - Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model
Presenter: Samer Salah
Session: Poster session 13
2010P - Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study
Presenter: Aleksander Antoniewicz
Session: Poster session 13
2011P - Neoadjuvant immunotherapy-driven bladder preservation for muscle-invasive bladder cancer: A multicenter, propensity score-matched cohort study
Presenter: Jiao Hu
Session: Poster session 13
2012P - Role of first-line immunotherapy in urothelial cancer with bone metastases: A national cancer database analysis of 3971 patients
Presenter: Zin Myint
Session: Poster session 13
2013P - First preliminary results of artificial intelligence generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project
Presenter: Gregor Duwe
Session: Poster session 13
2014P - Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
Presenter: Patrizia Giannatempo
Session: Poster session 13
2015P - Serum nectin-4: Prognostic and predictive value in bladder cancer?
Presenter: Kerstin Junker
Session: Poster session 13
2016P - Evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant (NAD) therapy
Presenter: Cora Sternberg
Session: Poster session 13
2017P - Intrinsic molecular difference between bladder and upper tract urothelial carcinomas and its impacts in treatment response
Presenter: Jiwon Kim
Session: Poster session 13